Secondary endpoints. Secondary safety endpoints include: · change from baseline in LV dimensions (end-systolic volume index, end-diastolic volume index, left ventricular mass) · change from baseline in regional (infarct related) and global wall motion score · change from baseline in ejection fraction · cardiac rupture · NT-proBNP 4 Investigational Plan
Appears in 5 contracts
Samples: License and Commercialization Agreement (Bellerophon Therapeutics, Inc.), License and Commercialization Agreement (Ikaria, Inc.), License and Commercialization Agreement (Bellerophon Therapeutics LLC)
Secondary endpoints. Secondary safety endpoints include: · change from baseline in LV dimensions (end-systolic volume index, end-diastolic volume index, left ventricular mass) · change from baseline in regional (infarct related) and global wall motion score · change from baseline in ejection fraction · cardiac rupture · NT-proBNP Annotated Protocol incorporating Amendment 1, Amendment 2, Amendment 3, and Amendment 4 Investigational Plan01 December 2008 Protocol BL-1040.01, Version 5.00 Safety and Feasibility study of BL-1040 Final CONFIDENTIAL
Appears in 2 contracts
Samples: License and Commercialization Agreement (BioLineRx Ltd.), License and Commercialization Agreement (BioLineRx Ltd.)
